Merck grows more ambitious about workhorse TROP2 ADC as partner Kelun posts phase 3 wins
8.5
来源：
FiercePharma
发布时间：
2025-10-20 14:07
摘要：
Merck's sac-TMT, an antibody-drug conjugate, has shown promising results in phase 3 trials for cervical cancer and HR-positive breast cancer, significantly reducing the risk of death and disease progression compared to chemotherapy. Backed by data from its partner Kelun, the drug has been approved in China for EGFR-mutant NSCLC, indicating strong market potential. Merck aims to replicate this success globally, navigating competitive landscapes in oncology.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
sacituzumab tirumotecan shows significant OS and PFS benefits in trials.
Kelun's data supports the efficacy of sac-TMT across multiple tumor types.
Chinese approval for sac-TMT as a second-line treatment enhances its market potential.
真实性检查
否
AI评分总结
Merck's sac-TMT, an antibody-drug conjugate, has shown promising results in phase 3 trials for cervical cancer and HR-positive breast cancer, significantly reducing the risk of death and disease progression compared to chemotherapy. Backed by data from its partner Kelun, the drug has been approved in China for EGFR-mutant NSCLC, indicating strong market potential. Merck aims to replicate this success globally, navigating competitive landscapes in oncology.